secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2026-09-24T11:15:56+00:00
Accession:  0001193125-26-400144
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan outlines Q4 2026 data readouts for CLN-978, velinotamig, CLN-049
-------------------------------------------------------------------------

- CLN-978 (CD19xCD3 TCE): multi-dose and single target dose data for SLE, RA, Sjögren's disease in December.
- Velinotamig (BCMAxCD3 TCE): Genrix Bio Phase 1 SLE multi-dose data at ACR Convergence 2026 on Nov 8, 2026.
- CLN-049 (FLT3xCD3 TCE): updated Phase 1 dose-escalation data in relapsed/refractory AML in December.
- CEO notes successful FDA meeting for CLN-049; registrational Phase 2 study planned to initiate.
- All data are from ongoing Phase 1 trials; no efficacy results disclosed yet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312526400144/0001193125-26-400144-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312526400144/cgem-20260924.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-400144

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer